Titan Pharmaceuticals, Inc. (TTNP)
Titan Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Petaling Jaya, KY. The stock last traded at $2.34, down 11.36% on the session, giving a market capitalisation of $3.1M. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of 1.38 implies it has historically moved more than the broad market.
Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.
Titan Pharmaceuticals, Inc. is most often compared with the following Healthcare names: